Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Bolen, Christopher R.; Mattiello, Federico; Herold, Michael; Hiddemann, Wolfgang; Huet, Sarah; Klapper, Wolfram; Marcus, Robert; Mir, Farheen; Salles, Gilles; Weigert, Oliver; Nielsen, Tina; Oestergaard, Mikkel Z.; Venstrom, Jeffrey M.

doi:10.1182/blood.2020008119

Cited by 24 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower grade (1/2) FL had a higher proportion of T REG EM 2 cells (Figure 6E, p = 0.002), whereas higher grade FL (3A) had a higher proportion of T FH cells (Figure 6F, p = 0.03). We applied digital cytometry [41] on the GALLIUM cohort [43, 44] to estimate the proportion of T REG EM 2 and T FH cells, and to investigate if these subsets were associated with progression-free survival. Indeed, there was a trend towards inferior prognosis in patients with higher proportions of T FH cells (p = 0.05, Supplementary Figure 7D), while no association was found for T REG EM 2 cells (p = 0.17, Supplementary Figure 7E).…”

Section: Resultsmentioning

confidence: 99%

Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities

Roider

Baertsch

Fitzgerald

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

T-cell-engaging immunotherapies have improved the treatment of nodal B-cell lymphoma, but responses vary highly. Future improvements of such therapies require better understanding of the variety of lymphoma-infiltrating T-cells. We employed single-cell RNA and T-cell receptor sequencing alongside quantification of surface proteins, flow cytometry and multiplexed immunofluorescence on 101 lymph nodes from healthy controls, and patients with diffuse large B-cell, mantle cell, follicular, or marginal zone lymphoma. This multimodal resource revealed entity-specific quantitative and spatial aberrations of the T-cell microenvironment. Clonal PD1+TCF7-but not PD1+TCF7+cytotoxic T-cells converged into terminally exhausted T-cells, the proportions of which were variable across entities and linked to inferior prognosis. In follicular and marginal zone lymphoma, we observed expansion of follicular helper and IKZF3+regulatory T-cells, which were clonally related and inversely associated with tumor grading. Overall, we portray lymphoma-infiltrating T-cells with unprecedented comprehensiveness and decipher both beneficial and adverse dimensions of T-cell response.

show abstract

Section: Resultsmentioning

confidence: 99%

Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities

Roider

Baertsch

Fitzgerald

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, discrimination for PFS was somewhat greater for FLIPI-L (Harrell's c-index 0.680 vs. 0.639, Figure S1C). features, 14,15 we explored the PFS advantage obtained by RM in the three FLIPI-L categories. We observed that low-risk FLIPI-L patients have similar PFS irrespective of first-line RM, while intermediateand high-risk FLIPI-L patients had significant longer PFS when they received RM, pointing to a predictive role of FLIPI-L with regard to post-induction strategies (Figure S3).…”

Section: Resultsmentioning

confidence: 99%

First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma

Mozas¹,

Rivero²,

Rivas‐Delgado³

et al. 2021

Hematological Oncology

View full text Add to dashboard Cite

The FLIPI-L has recently been proposed as a novel prognostic index in follicular lymphoma (FL), combining FLIPI and the presence of lymphopenia. In our single-center validation in 381 FL patients, lymphopenia was less frequent than in the original publication and thus the distribution of risk categories was different. Although it was not able to properly predict time to first treatment, FLIPI-L performed slightly better than FLIPI alone in the prediction of response, early relapse, progression-free and overall survival, and histological transformation.

show abstract

“…43 It is hypoth e sized that this inter ac tion may be driven by EZH2 muta tions, but this remains to be fur ther val idated. 41 In nonchemotherapy-containing reg i mens, m7-FLIPI was also not prognostic of out comes, rais ing the notion that che mother apy depen dence influ ences the high-risk sig na ture score. 44 To eval u ate the spe cific end point of POD24, Jurinovic et al 32 reexamined the m7-FLIPI.…”

Section: Combining Clin I Cal and Genetic Mod Elsmentioning

confidence: 99%

“…However, che mo therapy choice did have a sig nifi cant inter ac tion between PFS and the 23-gene sig na ture, in which patients with a high-risk score receiv ing CHOP/CVP had unfa vor able out comes com pared with those treated with bendamustine, suggesting che mo ther apy depen dence of the high-risk sig na ture score. 41 At pres ent, the assess ment of these immune mark ers and the capa bil ity to per form GEP stud ies are not stan dard ized at diagno sis, and some tech niques are not read ily avail able and hence remain part of a research approach.…”

Section: Tumor-based Bio Logic and Genetic Var I Ablesmentioning

confidence: 99%

Follicular lymphoma: is there an optimal way to define risk?

Casulo

2021

Hematology

View full text Add to dashboard Cite

Follicular lymphoma (FL) has a long natural history and typically indolent behavior. In the present era, there are a plethora of prognostic factors combining clinical, biological, and genetic data to determine patient prognosis and help develop treatment strategies over the course of a patient's lifetime. The rapid pace of tumor-specific and clinical advances in FL has created a challenge in the prioritization and implementation of these factors into clinical practice. Developing a comprehensive understanding of existing prognostic markers in FL will help select optimal ways of utilization in the clinical setting and investigate opportunities to define and intervene upon risk at FL diagnosis and disease recurrence.

show abstract

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Cited by 24 publications

References 16 publications

Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities

Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities

First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma

Follicular lymphoma: is there an optimal way to define risk?

Contact Info

Product

Resources

About